United Therapeutics (UTHR) Misses Q2 EPS, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. CDNS
2. AVGO
3. ANT
4. META
5. SSD
6. JBLU
7. PECO
8. AGYS
9. ARES
10. RMBS

Go back to United Therapeutics (UTHR) Misses Q2 EPS, Revenues Beat

United Therapeutics Corporation Reports Second Quarter 2022 Financial Results

August 3, 2022 6:00 AM EDT

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended June 30, 2022. Total revenues in the second quarter of 2022 grew 5% year-over-year to $466.9 million, compared to $446.5 million in the second quarter of 2021.

Im extraordinarily pleased with our business performance this past quarter, said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. The FDAs approval of our Tyvaso DPI medicine and recent major medical journal publications demonstrate our continuing product development... More